Juneau Biosciences

Juneau Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Juneau Biosciences is a private, pre-revenue biotech company dedicated to advancing women's health through genetic research and product development. Its core focus is on identifying genetic markers for endometriosis to create diagnostic tools and potential therapeutics, leveraging a population-based gene mapping approach. The company is actively recruiting participants and physicians for its genetic studies, indicating a research-heavy, early-stage operational model. Its success hinges on validating genetic discoveries and translating them into clinically viable products.

EndometriosisInfertility

Technology Platform

Population-based gene mapping for identifying genetic markers associated with women's health disorders, aimed at developing molecular diagnostics and therapeutics.

Funding History

1
SeedUndisclosed

Opportunities

The significant unmet need in endometriosis diagnosis (long delays, invasive confirmation) creates a major market for a non-invasive molecular test.
Furthermore, novel therapeutic targets derived from genetic research could address a lack of curative treatments in a large, underserved patient population.

Risk Factors

High scientific risk that genetic studies may not yield clinically actionable or commercially viable biomarkers.
As a pre-revenue private company, it faces substantial funding risk and may exhaust capital before reaching a key value inflection point.

Competitive Landscape

The competitive landscape for endometriosis is evolving. While historically underfunded, increasing investment in women's health is attracting new entrants. Competition exists from academic research consortia and a growing number of biotech startups, though Juneau's specific population-based approach in Utah may offer a unique advantage.